Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
120887252 | 12088725 | 2 | F | 20151214 | 20160915 | 20160218 | 20160929 | EXP | GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-111748 | RANBAXY | 0.00 | Y | 0.00000 | 20160929 | OT | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
120887252 | 12088725 | 1 | PS | RISPERIDONE. | RISPERIDONE | 1 | Oral | 4 MG, QD | 4 | MG | 77542 | 4 | MG | ||||||
120887252 | 12088725 | 2 | SS | CLOZARIL | CLOZAPINE | 1 | Oral | UNK | Y | U | 0 | TABLET | |||||||
120887252 | 12088725 | 3 | SS | CLOZARIL | CLOZAPINE | 1 | Oral | 25 MG, QD | Y | U | 0 | 25 | MG | TABLET |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
120887252 | 12088725 | 1 | Schizoaffective disorder |
120887252 | 12088725 | 2 | Schizoaffective disorder |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
120887252 | 12088725 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
120887252 | 12088725 | Neuroleptic malignant syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
120887252 | 12088725 | 1 | 20151214 | 0 | ||
120887252 | 12088725 | 2 | 20140429 | 0 | ||
120887252 | 12088725 | 3 | 20151214 | 20151215 | 0 |